Q4 FY2024 · ended Dec 31, 2024 · Revenue $0 · Filed Feb 23, 2026
Summit Therapeutics Inc. (SMMT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$160.2 million. As of Sep 30, 2026 it held $629.8 million in cash and investments and $20.0 million in total debt.
Revenue
$0
Net income
$-208.38M
+10.1% vs year-ago quarter
Operating cash flow
$-159.81M
-71.7% vs year-ago quarter
Free cash flow
$-160.21M
-72.0% vs year-ago quarter
EPS
$-0.26
+16.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
799.76M
+7.4% vs year-ago quarter
Net cash
$609.80M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SMMT (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Miami, FL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1599298
- Former names
- Summit Therapeutics plc (until Sep 17, 2020); Summit Corp plc (until Jan 30, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$208.4M | -$215.7M | -$189.4M | -$219.2M | -$231.8M |
| Diluted EPS | -$0.26 | -$0.28 | -$0.24 | -$0.29 | -$0.31 |
| Operating cash flow | -$159.8M | -$141.1M | -$122.3M | -$101.9M | -$93.1M |
| Free cash flow | -$160.2M | -$142.0M | -$122.5M | -$102.1M | -$93.2M |
| Total assets | $692.9M | $752.2M | $647.9M | $751.2M | $261.7M |
| Total liabilities | $128.2M | $122.2M | $101.9M | $92.3M | $69.5M |
| Stockholders' equity | $564.7M | $630.0M | $545.9M | $658.9M | $192.3M |
| Cash and investments | $629.8M | $690.7M | $598.7M | $713.4M | $238.6M |
| Total debt | $20.0M | $20.4M | $20.0M | $20.9M | $5.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Bylaw or fiscal year change, Shareholder vote results
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Bylaw or fiscal year change, Other events
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 13, 2026 |
All 564 Summit Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.